Sponsor

Genmab A/S

Denmark Carl Jacobsens Vej 30, 2500, Denmark

About the sponsor

Genmab A/S funds clinical research in advanced solid tumors, with activity across non-small cell lung cancer, endometrial cancer, ovarian cancer, cervical cancer, melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma, and triple-negative breast cancer.

Advanced malignant solid tumors
Metastatic cutaneous melanoma
Platinum-resistant ovarian cancer
Recurrent or metastatic cervical cancer

The portfolio includes studies in both monotherapy and combination therapy settings for recurrent, metastatic, and unresectable disease.

About Specializations

Genmab A/S runs clinical trials in conditions such as Neoplasm malignant, Ovarian cancer recurrent, Non-small cell lung cancer metastatic, Endometrial cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

26 clinical trials

Gastrooesophageal cancer+6

Recruiting

Registered drugNo placebo

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Glatiramer Acetate
Sponsor:Genmab A/S

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Registered drugNo placebo

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Registered drugNo placebo

Phase 2 Study of Rinatabart Sesutecan with PEGFILGRASTIM in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
Sponsor:Genmab A/S